↓ Skip to main content

The biology of Hepatocellular carcinoma: implications for genomic and immune therapies

Overview of attention for article published in Molecular Cancer, August 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (75th percentile)

Mentioned by

twitter
6 tweeters
patent
1 patent
googleplus
1 Google+ user

Citations

dimensions_citation
235 Dimensions

Readers on

mendeley
187 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The biology of Hepatocellular carcinoma: implications for genomic and immune therapies
Published in
Molecular Cancer, August 2017
DOI 10.1186/s12943-017-0712-x
Pubmed ID
Authors

Galina Khemlina, Sadakatsu Ikeda, Razelle Kurzrock

Abstract

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is a leading cause of cancer-related death worldwide. It is highly refractory to most systemic therapies. Recently, significant progress has been made in uncovering genomic alterations in HCC, including potentially targetable aberrations. The most common molecular anomalies in this malignancy are mutations in the TERT promoter, TP53, CTNNB1, AXIN1, ARID1A, CDKN2A and CCND1 genes. PTEN loss at the protein level is also frequent. Genomic portfolios stratify by risk factors as follows: (i) CTNNB1 with alcoholic cirrhosis; and (ii) TP53 with hepatitis B virus-induced cirrhosis. Activating mutations in CTNNB1 and inactivating mutations in AXIN1 both activate WNT signaling. Alterations in this pathway, as well as in TP53 and the cell cycle machinery, and in the PI3K/Akt/mTor axis (the latter activated in the presence of PTEN loss), as well as aberrant angiogenesis and epigenetic anomalies, appear to be major events in HCC. Many of these abnormalities may be pharmacologically tractable. Immunotherapy with checkpoint inhibitors is also emerging as an important treatment option. Indeed, 82% of patients express PD-L1 (immunohistochemistry) and response rates to anti-PD-1 treatment are about 19%, and include about 5% complete remissions as well as durable benefit in some patients. Biomarker-matched trials are still limited in this disease, and many of the genomic alterations in HCC remain challenging to target. Future studies may require combination regimens that include both immunotherapies and molecularly matched targeted treatments.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 187 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 187 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 25 13%
Student > Bachelor 25 13%
Student > Ph. D. Student 24 13%
Researcher 23 12%
Other 9 5%
Other 27 14%
Unknown 54 29%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 41 22%
Medicine and Dentistry 34 18%
Agricultural and Biological Sciences 12 6%
Pharmacology, Toxicology and Pharmaceutical Science 5 3%
Nursing and Health Professions 4 2%
Other 22 12%
Unknown 69 37%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 June 2021.
All research outputs
#4,106,097
of 21,392,919 outputs
Outputs from Molecular Cancer
#249
of 1,618 outputs
Outputs of similar age
#71,107
of 290,269 outputs
Outputs of similar age from Molecular Cancer
#1
of 1 outputs
Altmetric has tracked 21,392,919 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,618 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 290,269 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them